Skip to main content
    Z

    Zevra Therapeutics Inc. (ZVRA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.25
    +0.17 (+1.87%)

    Market Cap: $540.30M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Zevra Therapeutics Inc. (ZVRA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 3, 2026. Financial statements from company filings, amounts in US dollars.

    Zevra Therapeutics reported revenue of $106.47M for the fiscal year ended Dec 31, 2025, up 350.9% from the year before. That year, net income was $83.23M with a net margin of 78.2%, operating cash flow was -$1.60M and free cash flow was -$2.43M. The quarter ended Sep 30, 2026 had revenue of $37.76M and net income of $19.21M.

    Revenue and Margins

    The operating margin was -59.1% in the fiscal year ended Dec 2025, the lowest of the 3 years shown with an operating margin. Over the 6 years to Dec 2025, revenue grew from $12.84M, a compound annual rate of 42.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$106.47M+350.9%84.5%-59.1%78.2%
    Dec 2024$23.61M-14.0%68.6%-368.5%-446.9%
    Dec 2023$27.46M+170.3%92.1%-180.6%-167.7%
    Dec 2022$10.16M-64.5%97.8%-418.9%-263.5%
    Dec 2021$28.65M+115.6%92.8%27.0%-29.9%
    Dec 2020$13.29M+3.5%100.0%-42.2%-96.0%
    Dec 2019$12.84MN/A100.0%-158.4%-191.0%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$106.47M$23.61M$27.46M$10.16M$28.65M$13.29M$12.84M$0$0$0
    Cost of revenue$16.48M$7.42M$2.17M$222.00K$2.06M$0$0$0$0$0
    Gross profit$89.99M$16.20M$25.29M$9.94M$26.59M$13.29M$12.84M$0$0$0
    Research and development$12.74M$42.09M$39.81M$37.47M$10.16M$8.84M$19.41M$41.76M$20.59M$20.47M
    Operating income-$62.94M-$87.00M-$49.60M-$42.56M$7.73M-$5.61M-$20.34M-$55.90M-$33.37M-$37.48M
    Net income$83.23M-$105.51M-$46.05M-$26.77M-$8.55M-$12.76M-$24.52M-$56.47M-$43.39M-$16.52M
    EBITDA$88.64M-$79.47M-$48.08M-$27.04M$8.11M-$3.21M-$16.38M-$47.98M-$32.34M-$1.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$37.76M$39.66M$36.22M$34.13M$26.06M$25.88M$20.40M$12.04M$3.69M$4.45M$3.42M$12.92M
    Gross profit$35.96M$39.66M$34.32M$32.60M$24.82M$25.88M$19.06M$10.68M$1.39M$876.00K$3.25M$11.69M
    Operating income$11.58M$16.78M$52.15M$9.31M$4.14M-$71.04M-$5.36M-$15.42M-$27.31M-$23.80M-$20.49M-$15.16M
    Net income$19.21M$8.75M$37.89M$12.16M-$544.00K$74.71M-$3.10M-$35.74M-$33.23M-$19.93M-$16.62M-$19.89M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $62.35M by $59.00K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$284.73M$178.13M$172.33M$115.34M$132.94M$11.21M$10.51M$26.75M$52.46M$84.89M
    Current assets$223.01M$86.03M$86.94M$92.83M$115.06M$8.38M$6.97M$23.72M$45.90M$74.36M
    Cash and equivalents$62.41M$33.78M$43.05M$65.47M$112.35M$4.21M$3.22M$18.41M$10.87M$16.76M
    Total liabilities$130.07M$138.46M$110.46M$40.22M$5.82M$77.62M$84.96M$93.31M$109.97M$103.58M
    Short-term debt$419.00K$420.00K$37.70M$0$371.00K$390.00K$0$3.55M$3.52M$157.00K
    Long-term debt$61.93M$59.50M$5.07M$12.80M$0$68.05M$77.34M$78.11M$89.40M$91.17M
    Shareholder equity$154.66M$39.67M$61.86M$75.12M$127.12M-$66.41M-$74.46M-$66.57M-$57.52M-$18.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$313.57M$302.71M$278.58M$284.73M$270.12M$256.28M$172.71M$178.13M$191.55M$144.41M$151.28M$172.33M
    Total liabilities$74.65M$85.06M$72.78M$130.07M$136.95M$139.05M$131.69M$138.46M$121.78M$111.93M$102.47M$110.46M
    Cash and equivalents$122.15M$145.32M$95.59M$62.41M$54.44M$47.71M$37.34M$33.78M$54.04M$39.26M$42.85M$43.05M
    Shareholder equity$238.92M$217.65M$205.80M$154.66M$133.16M$117.23M$41.02M$39.67M$69.77M$32.48M$48.82M$61.86M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$1.60M-$69.67M-$33.53M-$18.72M$10.44M-$1.94M-$23.74M-$54.20M-$33.10M-$29.77M
    Capital expenditures$835.00K$0$296.00K$93.00K$102.00K$33.00K$26.00K$21.00K$181.00K$643.00K
    Free cash flow-$2.43M-$69.67M-$33.83M-$18.81M$10.34M-$1.97M-$23.76M-$54.22M-$33.28M-$30.41M
    Dividends paidN/AN/AN/A$324.00K$30.82MN/AN/AN/AN/AN/A
    Share repurchasesN/AN/A$3.45M$4.72M$1.34M$84.00K$0$184.00KN/AN/A
    Investing cash flow$18.13M-$22.16M-$17.39M-$36.72M-$15.52M-$33.00K$3.23M$33.33M$27.41M-$45.85M
    Financing cash flow$12.06M$82.11M$28.46M$8.35M$113.11M$2.74M$4.94M$28.02M-$203.00K$61.16M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$10.05M$17.03M$6.14M$5.52M$4.71M-$3.60M-$8.22M-$16.25M-$18.14M-$19.11M-$16.16M-$16.16M
    Capital expenditures$238.00K$217.00K$35.00K$31.00K$554.00K$213.00K$99.00K$0$0$0$0$72.00K
    Free cash flow$9.81M$16.82M$6.11M$5.49M$4.16M-$3.81M-$8.32M-$16.25M-$18.14M-$19.11M-$16.16M-$16.23M
    Last 12 quarters

    Frequently Asked Questions About ZVRA

    What is Zevra Therapeutics' annual revenue?

    Zevra Therapeutics reported revenue of $106.47M for the fiscal year ended Dec 31, 2025.

    How fast is Zevra Therapeutics' revenue growing?

    Revenue was up 350.9% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 118.8%.

    Is Zevra Therapeutics profitable?

    Yes. Zevra Therapeutics reported net income of $83.23M for the fiscal year ended Dec 31, 2025, with a net margin of 78.2%.

    How much free cash flow does ZVRA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$1.60M minus capital expenditures of $835.00K produced free cash flow of -$2.43M.

    How much debt does Zevra Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $61.93M, short-term debt of $419.00K and cash and equivalents of $62.41M.